title: Influence of subject age on the inhibition of oxidative metabolism by ciprofloxacin.
abstract: Case reports suggest that the magnitude of inhibition of oxidative metabolism produced by ciprofloxacin may be greater in elderly subjects. We examined the effect of oral ciprofloxacin on antipyrine disposition in 13 young (ages, 23 to 34 years) and 9 elderly (ages, 65 to 82 years) healthy volunteers. Ciprofloxacin decreased antipyrine oral clearance in young and elderly subjects (P less than 0.05), with the average decreases being similar in both groups (23.3% for the young subjects and 27.9% for the elderly subjects). Ciprofloxacin concentrations in serum were significantly higher (mean, 57%) in the elderly. The formation clearance of 4-hydroxyantipyrine and 3-hydroxymethylantipyrine was also significantly decreased in both groups of subjects; however, norantipyrine formation, accounting for 15 to 20% of antipyrine clearance, was reduced only in the elderly. These results suggest that elderly subjects are not more sensitive to the inhibitory effect of ciprofloxacin on antipyrine metabolism. However, careful clinical monitoring is necessary with all patients, irrespective of age, taking ciprofloxacin concomitantly with drugs primarily eliminated by the cytochrome P-450 system.
authors.affiliation: College of Pharmacy & Allied Health Professions, Wayne State University, Detroit, Michigan 48202.
authors.forename: N M
authors.initials: NM
authors.lastname: Waite
authors.forename: M J
authors.initials: MJ
authors.lastname: Rybak
authors.forename: D J
authors.initials: DJ
authors.lastname: Krakovsky
authors.forename: J D
authors.initials: JD
authors.lastname: Steinberg
authors.forename: L H
authors.initials: LH
authors.lastname: Warbasse
authors.forename: D J
authors.initials: DJ
authors.lastname: Edwards
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000375:Aging / Q000378:metabolism*; D000983:Antipyrine / Q000031:analogs & derivatives / Q000378:metabolism / Q000494:pharmacology / Q000652:urine; D002939:Ciprofloxacin / Q000494:pharmacology*; D000077553:Edaravone; D005260:Female; D006801:Humans; D008297:Male; D010084:Oxidation-Reduction; D011446:Prospective Studies
chemical_list: C007983:4-hydroxyantipyrine; C031820:3-hydroxymethylantipyrine; D002939:Ciprofloxacin; D000077553:Edaravone; D000983:Antipyrine